Rush Cancer Institute Section of Hematology is a clinical research site located in Chicago, Illinois, United States 60612-3824.
Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.
Rush Cancer Institute Section of Hematology has participated in 2 clinical trials.
Therapeutic areas: Multiple Myeloma.
Sponsors: Celgene Corporation, Celgene.
Is this your site? Claim your profile and control the information sponsors and patients see.
Browse all research sites in Illinois · View every site in Chicago
Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Rush Cancer Institute Section of Hematology has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Rush Cancer Institute Section of Hematology has 2 clinical trials on record. Their work covers Multiple Myeloma.
Rush Cancer Institute Section of Hematology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.